Treatment Decision-Making in Relapsed or Refractory Multiple Myeloma
Beth Faiman, CNP, PhD, Cleveland Clinic, Ohio, leads a series of detailed, case-based discussions on treatment for patients with relapsed/refractory multiple myeloma. Through this series, Faiman reviews diagnostic criteria, the evolving landscape for later-line therapies, and the practical use of novel therapies like CAR-T cell therapy and bispecific antibodies, such as talquetamab.
Faiman emphasizes individualized care based on disease aggressiveness, patient fitness, and shared decision-making, while also addressing the management of adverse effects like skin and oral toxicities. This series highlights the crucial role of advanced practice providers in guiding therapy, coordinating care teams, and supporting patients through complex treatment journeys.
Case 1: A Patient With Symptomatic Multiple Myeloma
Beth Faiman, CNP, PhD, discusses treatment decision-making for a patient with symptomatic relapsed multiple myeloma.
Case 2: A Patient With Multi-Relapsed Multiple Myeloma
Beth Faiman, CNP, PhD, discusses treatment decision-making for a patient with multiple myeloma whose disease relapsed through several lines of therapy.
The Advanced Practice Provider (APP) Institute is a new offering from the Oncology Learning Network that provides microburst education to oncology advanced practitioners. The platform offers year-round digital non-accredited learning modules through animated short videos, multimedia interviews with key opinion leaders, interactive content to test your knowledge, and more!
